|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Molecular diversity in AML1/ETO fusion transcripts in patients with t(8;21) positive acute myeloid leukaemia.
|
7523801 |
1994 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Approximately 12% of all new cases of AML are estimated to have AML1/ETO fusion transcripts and it is suggested that molecular screening should be performed in all cases with the possible exception of the M3 FAB type.
|
9432044 |
1997 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
For example, in acute myeloid leukemia (AML) higher epigenetic age-predictions are associated with increased incidence of mutations in RUNX1, WT1, and IDH2, whereas mutations in TET2, TP53, and PML-PARA translocation are more frequent in younger age-predictions.
|
26110659 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells.
|
25928846 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We cloned a novel RUNX1 chimeric gene generated by t(7;21)(q11.2;q22) in a patient with acute myeloid leukemia.
|
22661044 |
2012 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The t(8;21), which typically is associated with a distinct subtype of de novo acute myeloid leukemia (AML) carrying the aml1/eto fusion gene, was accompanied by increased bone marrow myeloblasts (33%) in case 1 and extramedullary myeloid sarcoma in case 2, suggesting its possible role in disease progression.
|
15198355 |
2004 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
A human homologue (CBFA2) was originally identified because of its involvement in the t(8;21) associated with a subtype of acute myeloid leukaemia.
|
7647375 |
1995 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
This proposed diagnostic group is supported by (i) retained myeloid differentiation potential during early T cell lymphoid development, (ii) recognition that some cases of acute myeloid leukaemia (AML) harbour hallmarks of T cell development, such as T-cell receptor gene rearrangements and (iii) common gene mutations in subsets of AML and T cell acute lymphoblastic leukaemia (T-ALL), including WT1, PHF6, RUNX1 and BCL11B.
|
29441563 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Quantitative analysis of AML1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukaemia.
|
7577620 |
1995 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Although several cooperative and exclusive mutation patterns were observed, the accumulated mutation number was higher in cytogenetically normal AML and lower in AML with RUNX1-RUNX1T1 and CBFB-MYH11, indicating a strong potential of these translocations for the initiation of AML.
|
24487413 |
2014 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Somatically acquired point mutations of AML1/RUNX1 gene have been recently identified in rare cases of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
|
12393679 |
2003 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Therefore, we developed a Caspase-3 knockout genetic mouse model of AML and found that loss of Caspase-3 actually delayed AML1-ETO9a (AE9a)-driven leukemogenesis, indicating that Caspase-3 may play distinct roles in the initiation and/or progression of AML.
|
28381396 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
The fusion gene AML1-ETO initially dysregulates various cell cycle molecules in t(8;21) acute myeloid leukemia.
|
31207577 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
While RUNX1 can function as a tumor suppressor, recent data have shown that RUNX1 is required for AML cell survival.
|
26590920 |
2016 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
NPM1 gene mutations are the most frequent genetic lesion in the 60% of adult acute myeloid leukemias (AMLs) with normal karyotype and no evidence of typical fusion genes (BCR/ABL1, PML/RARA, AML1/ETO, CBFB/MYH11, DEK/CAN).
|
16645213 |
2006 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
RUNX1 amplification in lineage conversion of childhood B-cell acute lymphoblastic leukemia to acute myelogenous leukemia.
|
17889714 |
2007 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Thus, we identified C11orf41 as a novel fusion partner of RUNX1 in AML.
|
23102734 |
2012 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, a new cell line was established which will be useful for the study of AML with normal cytogenetics and mutations in NRAS and/or RUNX1.
|
19414191 |
2009 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
This finding increases our understanding of the mechanisms by which the AML1/ETO protein may contribute to modified gene expression linked to the onset and progression of t(8;21) related acute myelogenous leukemia.
|
10906759 |
2000 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Here we identify somatic mutations in additional sex combs-like 2 (ASXL2) in 22.7% (25/110) of patients with t(8;21), but not in patients with inv(16)/t(16;16) (0/60) or RUNX1-mutated AML (0/26).
|
24973361 |
2014 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Levels of native RUNX1T1 mRNA were low in both healthy and RUNX1-RUNX1T1-negative AML samples.
|
19891700 |
2010 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Terminal deoxynucleotidyl transferase (TdT) expression in AML-M0 has been proposed by others as a surrogate for RUNX1 (runt-related transcription factor 1) mutations, a mutation associated with distinct gene expression profiles in AML-M0.
|
22936064 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Common fusion transcripts in childhood acute lymphoblastic leukemia (ALL) are TEL-AML1, E2A-PBX, MLL-AF4, and BCR-ABL (p190) and in acute nonlymphoblastic leukemia (ANLL) are AML-ETO, PML-RARA, and CBFB-MYH11.
|
18665825 |
2008 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Thus, the targeting and suppression of CTSG by AML1-ETO in t(8;21) AML may provide a mechanism for leukemia cells to escape from the intracellular surveillance system by preventing degradation of foreign proteins.
|
22641217 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
We serially monitored AML1-ETO fusion transcripts using RQ-PCR in 113 bone marrow or peripheral blood samples from 21 patients with AML1-ETO-positive acute myeloid leukemia and analyzed the prognostic relevance of the results.
|
16266896 |
2005 |